Platinum open access journal
pISSN 2466-0493 eISSN 2466-054X
Indexed in MEDLINE, SCIE, Scopus, DOAJ and more
    Korean J Urol. 2006 Feb;47(2):195-200. Korean.
    Published online Feb 28, 2006.
    https://doi.org/10.4111/kju.2006.47.2.195
    Copyright © 2006 The Korean Urological Association
    Original Article

    The Effects of Selective Cyclooxygenase-2 Inhibitor and Prostaglandin E2 Receptor Agonists on the Endothelin Axis of Prostate Cancer Cells

    Tae Hyoung Kim, Young Sun Kim, Soon Chul Myung, Seung Woon Lee, Eun Ha Won and Tae Houng Kim
      • Department of Urology, College of Medicine, Chung-Ang University, Seoul, Korea.
    • Corresponding author (Email: kthlmk@hanafos.com )
    Received August 30, 2005; Accepted October 08, 2005.

    Abstract

    Purpose

    The enhanced expression of the cyclooxygenase-2 (COX-2), prostaglandin E2 receptor (EPs) and endothelin-1 (ET-1) axis is known to play a significant role in the development and progression of several malignancies. To date, little work has been done to investigate the relationships between the COX-2, EPs and ET-1 axis in prostate cancer (PC) cells. The aim of this study is to investigate the expression of preproET-1 (PPET-1), ET-1 receptor A (ETAR), and endothelin converting enzyme-1 (ECE-1) in the PC cell lines and to evaluate the effects of COX-2 and EPs on the expression of PPET-1, ETAR, and ECE-1.

    Materials and Methods

    Two PC cell lines, PC-3 and DU-145 cells were used for this study. By performing reverse transcription polymerase chain reaction (RT-PCR), the mRNA expressions of PPET-1, ETAR and ECE-1 were detected, and then the mRNA expressions of PPET-1, ETAR and ECE-1 were detected after being treating the cells with selective COX-2 inhibitor (NS-398), or EP2 (butaprost) and EP4 (misoprostol), which are both agonist of 10-10, 10-8 and 10-6M.

    Results

    PPET-1, ETAR and ECE-1 mRNA were expressed in both cell lines. After NS-398 treatment, only the PPET-1 mRNA expression was decreased at 4, 8 and 12 hours in the PC-3 cells. EP2 and EP4 agonist induced an increase for the PPET-1, ETAR and ECE-1 mRNA expressions, compared with the NS-398 treated group (control), in the PC-3 cells.

    Conclusions

    ET-1/ETAR and ECE-1, whose expressions are increased by EP2 and EP4, may play key roles in the development and progression of PC via COX-2. A combination treatment with selective inhibitors for COX-2, EPs and ETAR would be novel approach to prostate cancer therapy.

    Keywords
    Prostate cancer; Cells; Cyclooxygenase-2; PGE2 receptors; Endothelins

    Figures

    Fig. 1
    PC-3 and DU-145 cells express preproET-1 (PPET-1), ET-1 receptor A (ETAR), and endothelin converting enzyme-1 (ECE-1) (M: marker, 1: PC-3, 2: DU-145).

    Fig. 2
    Time course of the preproET-1 (PPET-1) mRNA expression in the PC-3 and DU-145 cells. The PPET-1 mRNA expression is decreased in the PC-3 cells at 4, 8 and 12 hours after NS-398 10µM treatment (C: control).

    Fig. 3
    The preproET-1 (PPET-1) mRNA expression in the PC-3 and DU-145 cells after NS-398 and NS-398 treatment along with various concentration of EP2 and EP4 agonist. The EP2 and EP4 agonists induce an increase in the PPET-1 mRNA expression in the PC-3 cells compared with the NS-398 10µM treated group (control), but the PPET-1 mRNA expression is not changed in the DU-145 cells (1: NS-398 10µM treated group (control), 2, 3, 4: 1 with 10-10, 10-8, 10-6M of EP2 agonist, 5, 6, 7: 1 with 10-10, 10-8, 10-6M of EP4 agonist).

    Fig. 4
    The ET-1 receptor A (ETAR) mRNA expression in the PC-3 and DU-145 cells after NS-398 and NS-398 treatment along with treatment with various concentration of EP2 and EP4 agonists. EP2 and EP4 agonists induce an increase in the ETAR mRNA expression in the PC-3 cells, compared with the NS-398 10µM treated group (control) of PC-3 cells, but the ETAR mRNA expression is not changed in the DU-145 cells (1: NS-398 10µM treated group (control), 2, 3, 4: 1 with 10-10, 10-8, 10-6M of EP2 agonist, 5, 6, 7: 1 with 10-10, 10-8, 10-6M of EP4 agonist).

    Fig. 5
    The endothelin converting enzyme-1 (ECE-1) mRNA expression in the PC-3 and DU-145 cells after NS-398 and NS-398 treatment along with various concentration of EP2 and EP4 agonist treatment. EP2 and EP4 agonists induce an increase in the ECE-1 mRNA expression in the PC-3 cells, compared with NS-398 10µM treated group (control), but the ECE-1 mRNA expression is not changed in the DU-145 cells (1: NS-398 10µM treated group (control), 2, 3, 4: 1 with 10-10, 10-8, 10-6M of EP2 agonist, 5, 6, 7: 1 with 10-10, 10-8, 10-6M of EP4 agonist).

    Tables

    Table 1
    Primer sequence for RT-PCR

    References

      1. Korea Statistical Information System. National Statistical Office. Republic of Korea.
        Available from: URL: http://kosis.nso.go.kr.
      1. Lara PN Jr, Meyers FJ. Treatment options in androgen-independent prostate cancer. Cancer Invest 1999;17:137–144.
      1. Masferrer JL, Zweifel BS, Manning PT, Hauser SD, Leahy KM, Smith WG, et al. Selective inhibition of inducible cyclooxygenase-2 in vivo is antiinflammatory and non-ulcerogenic. Proc Natl Acad Sci USA 1994;91:3228–3232.
      1. Chaudry AA, Wahle KW, McClinton S, Moffat LE. Arachidonic acid metabolism in benign and malignant prostatic tissue in vitro: effects of fatty acids and cyclooxygenase inhibitors. Int J Cancer 1994;57:176–180.
      1. Trevisani A, Ferretti E, Capuzzo A, Tomasi V. Elevated levels of prostaglandin E2 in Yoshida hepatoma and the inhibition of tumour growth by non-steroidal anti-inflammatory drugs. Br J Cancer 1980;41:341–347.
      1. Iwasaki Y, Iwasaki J, Freake HC. Growth inhibition of human breast cancer cells induced by calcitonin. Biochem Biophys Res Commun 1983;110:235–242.
      1. Rudland PS, Twiston-Davies AC, Tsao SW. Rat mammary preadipocytes in culture produce a trophic agent for mammary epithelia-prostaglandin E2. J Cell Physiol 1984;120:364–376.
      1. Bandyopadhyay GK, Imagawa W, Wallace D, Nandi S. Linoleate metabolites enhance the in vitro proliferative response of mouse mammary epithelial cells to epidermal growth factor. J Biol Chem 1987;262:2750–2756.
      1. Kim TH, Kim YS, Myoung SC, Lee JH, Won EH. Prostaglandin E receptor II and IV increase the expression of matrix metalloproteinase-7 in PC (prostate cancer)-3 cells. Korean J Urol 2004;45:478–484.
      1. Yanagisawa M, Kurihara H, Kimura S, Tomobe Y, Kobayashi M, Mitsui Y, et al. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature 1988;332:411–415.
      1. Masaki T. The endothelin family: an overview. J Cardiovasc Pharmacol 2000;35 4 Suppl 2:S3–S5.
      1. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110–116.
      1. Bagnato A, Catt KJ. Endothelin as autocrine regulators of tumor cell growth. Trends Endocrinol Metab 1998;9:378–383.
      1. Bagnato A, Natali PG. Endothelin receptors as novel targets in tumor therapy. J Transl Med 2004;2:16.
      1. Nelson JB, Hedican SP, George DJ, Reddi AH, Piantadosi S, Eisenberger MA, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944–949.
      1. Grant ES, Brown T, Roach A, Williams BC, Habib FK. In vitro expression of endothelin-1 (ET-1) and ETA and ETB ET receptors by the prostatic epithelium and stroma. J Clin Endocrinol Metab 1997;82:508–513.
      1. Usmani BA, Harden B, Maitland NJ, Turner AJ. Differential expression of neutral endopeptidase-24.11 (neprilysin) and endothelin converting enzyme in human prostate cancer cell lines. Clin Sci 2002;103 Suppl 48:S314–S317.
      1. Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc Natl Acad Sci USA 1997;94:3336–3340.
      1. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya S, et al. Acceleration of intestinal polyposis through prostaglandin receptor EP2 in ApcΔ716 knockout mice. Nat Med 2001;7:1048–1051.
      1. Naraba H, Yokoyama C, Tago N, Murakami M, Kudo I, Fueki M, et al. Transcriptional regulation of the membrane-associated prostaglandin E2 synthase gene. Essential role of the transcription factor Egr-1. J Biol Chem 2002;277:28601–28608.
      1. Yoshimatsu K, Golijanin D, Paty PB, Soslow RA, Jacobsson PJ, DeLellis RA, et al. Inducible microsomal prostaglandin E synthase is overexpressed in colorectal adenomas and cancer. Clin Cancer Res 2001;7:3971–3976.
      1. Pratt PF, Bokemeyer D, Foschi M, Sorokin A, Dunn MJ. Alterations in subcellular localization of p38 MAPK potentiates endothelin-stimulated COX-2 expression in glomerular mesangial cells. J Biol Chem 2003;278:51928–51936.
      1. Spinella F, Rosanò L, Di Castro V, Nicotra MR, Natali PG, Bagnato A. Inhibition of cyclooxygenase-1 and cyclooxygenase-2 expression by targeting the endothelin A receptor in human ovarian carcinoma cells. Clin Cancer Res 2004;10:4670–4679.
      1. Spinella F, Rosanò L, Di Castro V, Natali PG, Bagnato A. Endothelin-1-induced prostaglandin E2-EP2, EP4-signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. J Biol Chem 2004;279:46700–46705.
      1. Tran J, Master Z, Yu JL, Rak J, Dumont DJ, Kerbel RS. A role for survivin in chemoresistance of endothelial cells mediated by VEGF. Proc Natl Acad Sci USA 2002;99:4349–4354.
    MeSH Terms
    Axis, Cervical Vertebra*
    Cell Line
    Cyclooxygenase 2*
    Dinoprostone*
    Endothelin-1
    Endothelins*
    Polymerase Chain Reaction
    Prostate*
    Prostatic Neoplasms*
    RNA, Messenger
    Receptors, Prostaglandin E
    Reverse Transcription
    Metrics
    Share
    Figures
    slide
    slide
    slide
    slide
    slide

    1 / 5

    Tables
    slide

    1 / 1

    PERMALINK